Nano-Silicon Drug Delivery Platform Addresses Drug Rejection and Enables Safe and Effective Targeting of New Drugs

 

Nano-silicon drug delivery platform is an excellent candidate for medical applications as drug delivery devices, due to excellent biocompatibility, biodegradability, and high surface area of porous silicon nanoparticles. Nanoporous silicon is found naturally on the silicon-based carbon sheets of solar cells, and in semiconductor wafers. It has recently found its way to the exterior of drugs, where it is said to have many anti-inflammatory properties.


 

The unique feature of this material is that it absorbs almost all of the energy input before it passes through the skin. This property is known as absorption, and it allows many pharmaceuticals, including some commonly used drugs, to be absorbed into the body without rejection.Nano-silicon drug delivery platform offers an easy solution to the problem of drug rejection, since only very small concentrations are needed to get a drug to the intended site. As the pores of the nanoporous silicon-based drug delivery membrane open, more of the drug is absorbed. This process can also be used to protect against skin infections from drug aerosols.

The porous silicon nano-colored membranes are made from hollow tubes filled with liquid medium, similar to the way a tire pump works. Silicon is sprayed on the liquid medium, which is then allowed to dry, becoming a sort of bond coating. The nanomolar is non-reactive, and it is designed to attach easily to the surface of the skin. The nanoprofertilized coating is then etched away by the skin, leaving a smooth, flat surface. This coating is particularly effective for medical laser applications.

Although, the healthcare sector has witnessed significant advancements in R&D of medicines, challenge still lies in getting these medicines to the right place in the body and at the right dose. Nano-silicon drug delivery platform enables safe and effective targeting of new drugs and also helps controlled release of older drugs. Such advantages have led to increasing investment in next-gen silicon nanotechnology drug delivery platforms. For instance, in November 2020, SiSaf Ltd, the U.K.-based developer of drugs using bio-courier technology, raised US$ 13.2 million in Series B financing.

Comments

Popular posts from this blog

Increasing Initiatives to Digitalize the Healthcare Sector Is Expected To Boost Demand for Electronic Medical Records

Ureteroscopes are highly preferred option over traditional ureteroscopy

Pharmacy Benefit Management is an Integral Part of the Medicare System